Key Points
- Muneer Satter, an Annexon director, bought 400,000 shares on Nov. 20 at $4.48 each for $1.792M, increasing his stake to 9,306,024 shares (a 4.49% hike) valued at about $41.69M.
- Annexon shares traded flat at $4.27 with elevated volume (3.83M vs. a 1.77M average), a market cap of $510.8M, and a 12‑month range of $1.28–$5.66.
- The company missed quarterly EPS estimates and shows a negative P/E (-3.31); analysts are mixed with an average rating of "Hold" and an average price target of $17.33.
Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director Muneer Satter purchased 400,000 shares of the firm's stock in a transaction that occurred on Thursday, November 20th. The shares were bought at an average price of $4.48 per share, with a total value of $1,792,000.00. Following the completion of the acquisition, the director owned 9,306,024 shares of the company's stock, valued at $41,690,987.52. This trade represents a 4.49% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Annexon Price Performance
Annexon stock remained flat at $4.27 during trading hours on Friday. 3,830,149 shares of the company's stock traded hands, compared to its average volume of 1,768,223. Annexon, Inc. has a 1 year low of $1.28 and a 1 year high of $5.66. The firm has a market capitalization of $510.83 million, a price-to-earnings ratio of -3.31 and a beta of 1.28. The company's fifty day moving average is $3.09 and its two-hundred day moving average is $2.58.
Annexon (NASDAQ:ANNX - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.03). As a group, analysts expect that Annexon, Inc. will post -0.96 EPS for the current year.
Hedge Funds Weigh In On Annexon
Institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its stake in shares of Annexon by 25.2% during the 1st quarter. Bank of New York Mellon Corp now owns 288,698 shares of the company's stock worth $557,000 after acquiring an additional 58,152 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Annexon in the 1st quarter valued at approximately $127,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Annexon by 164.1% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,026 shares of the company's stock worth $66,000 after purchasing an additional 21,143 shares during the last quarter. XTX Topco Ltd boosted its position in Annexon by 65.4% during the first quarter. XTX Topco Ltd now owns 58,130 shares of the company's stock worth $112,000 after purchasing an additional 22,979 shares during the period. Finally, J. Safra Sarasin Holding AG grew its holdings in Annexon by 63.4% during the first quarter. J. Safra Sarasin Holding AG now owns 254,538 shares of the company's stock valued at $491,000 after purchasing an additional 98,794 shares during the last quarter.
Wall Street Analysts Forecast Growth
ANNX has been the topic of a number of recent research reports. HC Wainwright restated a "buy" rating and issued a $14.00 target price on shares of Annexon in a research note on Friday, August 15th. Zacks Research raised Annexon from a "strong sell" rating to a "hold" rating in a research note on Monday, August 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Annexon in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company increased their price objective on Annexon from $14.00 to $27.00 and gave the stock an "overweight" rating in a report on Wednesday. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $17.33.
Check Out Our Latest Stock Report on Annexon
Annexon Company Profile
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
